8.88
-0.4(-4.31%)
Currency In HKD
Address
New Bund Times Square
Shanghai, 201203
China
Phone
86 21 6033 5000
Website
Sector
Healthcare
Industry
Biotechnology
Employees
135
First IPO Date
February 26, 2019
| Name | Title | Pay | Year Born |
| Dr. Jianxin Yang M.D., Ph.D. | Chief Executive Officer, President of R&D and Executive Director | 7.86M | 1964 |
| Mr. Michael J. Choi M.B.A. | Chief Business & Strategy Officer | 0 | 1975 |
| Dr. Qingmei Shi M.D., Ph.D. | Senior Vice President & Chief Medical Officer | 0 | 1976 |
| Ms. Weicong Ni | Chief Financial Officer & Joint Company Secretary | 0 | 1991 |
| Ms. Ying Hua Zhang | Senior Vice President & Chief Operating Officer | 0 | 1979 |
| Dr. Yujuan La Ph.D. | Senior Vice President of Product Development | 0 | 1978 |
| Ms. Mei Yee Yung FCIS, FCS | Joint Company Secretary | 0 | 1965 |
CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.